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Objective: The purpose of this study was to evaluate the effectiveness of demineralized bone matrix
(DBM) with and without platelet-rich plasma (PRP) in the treatment of osteochondral defects (OCDs) of
the talus. We hypothesized that treatment with DBM would result in more bone formation than no
treatment in control OCDs, and that PRP would further enhance the regenerative capacity of DBM.
Method: A standardized 6-mm OCD was created in each talus of 16 adult goats. According to a
randomization scheme, one OCD of each goat was treated with allogeneic DBM hydrated with normal
saline (n ¼ 8) or hydrated with autologous PRP (n ¼ 8). The contralateral OCD (n ¼ 16) served as control.
After 24 weeks, the animals were euthanized and the tali excised. Various outcome parameters were
analyzed with use of macroscopic evaluation, micro-computed tomography (mCT), histology, histo-
morphometry, and ﬂuorescence microscopy.
Results: None of the analyses revealed statistically signiﬁcant differences between the groups for any of
the parameters analyzed in any volume of interest. For example, the mean bone volume fraction (BV/TV)
of the defect, as measured by mCT, was 0.56 (95% conﬁdence interval [CI], 0.44e0.68) for DBM hydrated
with normal saline and 0.52 (95% CI, 0.40e0.65) for DBM hydrated with PRP, compared to 0.53 (95% CI,
0.45e0.61) and 0.54 (95% CI, 0.44e0.64) for the internal controls, respectively (P > 0.05).
Conclusion: In contrast to our hypotheses, no beneﬁcial treatment effect of DBM with or without PRP was
found for OCDs of the caprine talus.
 2013 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.Introduction
In the treatment of talar osteochondral defects (OCDs), repair of
the subchondral bone is an important aim of the procedure1. The
presence of subchondral bone is essential for survival of chon-
drocytes2. The affected subchondral bone is thought to cause the.J.A. van Bergen, Orthopaedic
opaedic Surgery, Academic
ef 9, 1105 AZ Amsterdam, The
.
an Bergen), g.m.kerkhoffs@
otmail.com (M. Özdemir),
.nl (V. Everts), lvruijven@
. van Dijk), l.blankevoort@
s Research Society International. Ppain3. Restoration of the subchondral bone may improve the
weight-bearing capacity of the ankle and prevent further cyst
formation.3
Urist pioneered the use of demineralized bone matrix (DBM) for
bone defects4,5. Since his work, there has been increasing experi-
ence with DBM in both animals4,6e8 and humans9,10. The sequence
of events after implantation of DBM mirrors that of endochondral
ossiﬁcation4. Bone morphogenetic proteins (BMP-2, -4, and -7)
seem to be responsible for the formation of bone and possibly
cartilage that are induced by DBM11,12. The BMPs present in DBM
attract mesenchymal stem cells through chemotaxis and act as
morphogens that may direct the differentiation of these cells into
an osteochondrogenic lineage. Different ﬂuids can be used for
rehydration of the DBM before application, including normal saline,
bone marrow aspirate, antibiotics solution, whole blood, or platelet
concentrate.ublished by Elsevier Ltd. All rights reserved.
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tains concentrated growth factors, including transforming growth
factor-b (TGF-b) and platelet-derived growth factor (PDGF)13,14.
TGF-b in PRP may stimulate chemotaxis and mitogenesis of oste-
oblast and chondroblast precursors and inhibit osteoclast forma-
tion and bone resorption15,16. PDGF may promote mitogenesis,
angiogenesis, and chondrocyte proliferation15e17. Although, in
theory, PRP may enhance the biologic activity of DBM, the combi-
nation of DBM and PRP has had contradictory results.15,18,19
The purpose of the present study was to evaluate the effec-
tiveness of DBM with or without PRP in the treatment of ankle
OCDs in goats. We hypothesized that (1) treatment with DBM
would repair more bone than control OCDs, and that (2) PRP would
further enhance the regenerative capacity of DBM.Materials and methods
Animals and experimental design
The study was approved by the Animal Care and Use Com-
mittee of the University of Amsterdam. A caprine model was
used, speciﬁcally designed for ankle OCDs20. Sixteen adult female
Dutch milk goats (Capra Hircus Sana) were included with an
approximate age of 4 years. All goats were healthy, according to
physical examination and blood tests performed by a veteri-
narian. The goats were weighed on a digital scale before surgery
and at ﬁnal follow-up. Surgery was performed in a sterile manner
on both ankles, with the goat under general anesthesia with
endotracheal intubation. A single intramuscular dose with pro-
phylactic antibiotics (Pen & Strep, Fendigo sa/nv, Brussels,
Belgium) was injected preoperatively. The ankle joint was
exposed through a posteromedial approach. Normal articular
surfaces were conﬁrmed by visual inspection. Standard OCDs of
6 mm in diameter and depth were created with specially
developed instruments20. According to a predeﬁned randomiza-
tion scheme, one defect of each goat was treated with DBM hy-
drated either with normal saline (0.9% NaCl solution) (“DBM
treatment”; n ¼ 8) or with PRP (“DBM þ PRP treatment”; n ¼ 8),
and the other served as a control (“DBM control” or “DBM þ PRP
control”). In each case, the material was inserted press-ﬁt up to
the level of the adjacent cartilage surface. The joint capsule and
skin were closed in a standard fashion.20
During recovery, the animals were kept outdoors in a large
natural environment, without activity restrictions, and with food
ad libitum. Eating habits, ambulatory activities, and health status
were monitored daily.
Since previous studies showed no substantial change in repair of
knee OCDs after 24 weeks21,22, the goats were euthanized 24weeks
after surgery by injecting a lethal intravenous dose of pentobar-
bital. All analyses were performed by observers blinded to the
treatment provided.DBM
Commercially available cortical DBM (Bonus DBM, Biomet
BV, the Netherlands) was used. This DBM was obtained from
human donors from qualiﬁed tissue banks that were registered
with the FDA and accredited by the American Association of
Tissue Banks. It was granulated, demineralized with organic
solvents, freeze-dried (i.e., lyophilized) and processed aseptically.
This process resulted in calcium levels of less than 0.1%12. It was
combined with a collagen-derived carrier (gelatin) from the same
donor, packaged in a rehydration syringe, and sterilized by
gamma irradiation.PRP
Autologous PRP was used for rehydration of the DBM. After in-
duction of anesthesia and before surgery, 27 ml venous goat blood
was aspirated into a 30-ml syringe that contained 3 ml of antico-
agulant citrate dextrose A. PRP was isolated by centrifugation at
3200 rpm for 15 min using the gravitational platelet system II (GPS
II, Biomet BV, the Netherlands). This preparation system produces
3 ml of PRP with a reported eightfold increase in platelet concen-
tration and a fourfold to sevenfold increase in growth factor con-
centration compared with whole blood23e25. The concentration of
platelets in the PRP of each subject in the present study was
measured using an automated hematology analyzer (XE-5000,
Sysmex, Japan) after 5 min of resuspension on a rocker, as recom-
mended byWoodell-May et al.24 Themedian platelet concentration
of the PRP was 1511  109/l (range, 82e2090  109/l).
Macroscopy
After the goats were euthanized, the tali were excised and
digital high-resolution photographs were taken of the talar artic-
ular surfaces. Two independent observers macroscopically graded
the photographs with use of the validated International Cartilage
Repair Society (ICRS) cartilage repair assessment26,27. This score
ranges from 0 to 12 points and is subdivided into degree of defect
repair, integration to border zone, and macroscopic appearance (4
points each), with a score of 12 indicating a completely normal
appearance. The scores of the two observers were averaged and
outliers with a difference of more than 1 point were scored by
consensus.28
Micro-computed tomography (mCT)
The anterior part of the talus, at safe distance from the OCD, was
sawn off with a water-cooled band saw to reduce the size of the
specimen, allowing it to be placed in the mCT scanner, and to
optimize penetration of ﬁxative into the specimen. After 1 week in
ﬁxative (4% phosphate-buffered formaldehyde), the specimens
were submerged in 70% ethanol and temporarily subjected to a
vacuum. In the 70% ethanol solution, they were placed in a mCT
scanner (mCT 40, Scanco Medical AG, Bassersdorf, Switzerland) and
scanned with a resolution of 18 mm. To minimize the noise in the
reconstructions, an integration time of 1000 ms was used.
mCT reconstructions were segmented with a threshold level of
467 mg HA/cm3. Two 3-dimensional cylindrical volumes of interest
were deﬁned: one representing the complete OCD (6 mm in
diameter and depth), and one representing the central OCD (3 mm
in diameter and 5 mm in depth) (Fig. 1). Using morphometric
software (Scanco Medical AG, Bassersdorf, Switzerland), the
following parameters were analyzed: bone volume fraction (BV/TV,
bone volume (BV)/tissue volume (TV)), tissue mineral density
(TMD) of BV and of TV, and trabecular number (Tb.N), thickness,
and separation. The BV/TV was the primary outcome of the study.
Histology
After ﬁxation, the specimens were dehydrated using ascending
grades of alcohol and embedded inmethyl-methacrylate. After cold
polymerization, the undecalciﬁed specimens were cut into 5-mm
sections with a Jung-K microtome (R. Jung, Heidelberg, Germany).
Thirty central sectionswere obtained of each specimen to overcome
sampling error. Every third section was stained with Goldner’s tri-
chrome method or toluidine blue for light microscopy, or left un-
stained for ﬂuorescence microscopy. Two observers simultaneously
assessed the stained sections and identiﬁed the type of healing.
Fig. 1. mCT analysis. Transverse cross-section of the talus (left) and the two cylindrical volumes of interest representing the complete defect (middle) and the central 3  5 mm
(right).
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A representative Goldner-stained mid-section of each talus was
analyzed using a Leica DMRA microscope that was connected to
Leica Qwin computer software (Leica Microsystems Imaging Solu-
tions, Cambridge, UK) with a custom-made routine for quantitative
measurements of bone parameters. Two observers simultaneously
made the choice for the representative section, based on technical
quality and overall appearance. Three areas of interest were
deﬁned: (1) the center of the OCD, (2) sides and bottom of the
defect (close to the lateral, medial, and deep borders), and (3) the
surface (close to the articular surface of the defect)20. For each area
of interest, one (surface), two (center) or three (sides and bottom)
representative measurement ﬁelds of 3.07  105 mm2 were digi-
tized at a magniﬁcation of 200. Mineralized bone surface area
(bone%) and osteoid surface area (osteoid%) were assessed. The
numbers of osteocytes, osteoblasts, and osteoclasts were counted at
a magniﬁcation of 400 and expressed per area of mineralized
bone tissue. These histomorphometric measurements have been
shown excellent intraobserver and interobserver reliability.20
Fluorescence microscopy
Fluorochrome labels were administered at week 1 (Oxy-
tetracyclin yellow, 32 mg/kg intramuscularly) and weeks 6, 12, 18,
and 23 (Calcein green, 20 mg/kg subcutaneously). Fluorescence
microscopy was used with ﬂuorescence ﬁlters and unstained sec-
tions to analyze the speed of bone regeneration (mineral apposition
rate (MAR)). Six measurement ﬁelds (magniﬁcation, 400) were
digitized, similar to the areas of interest of histomorphometry. The
distance between two consecutive ﬂuorescent bone labels was
measured at approximately 10 locations within a measurement
ﬁeld by an independent observer blinded to treatment allocation.
The MAR (mm/day) was calculated as the average distance divided
by the number of days between two injections.
Statistical analysis
The sample size was calculated before the start of the study and
was based on the primary outcome BV/TV. Prior data from a pilot
study indicated that the standard deviation of BV/TV in the central
3 mm of the OCDs treatedwith DBMwas 0.08620. With an intended
difference in themean BV/TV of matched pairs of 0.10, a sample size
of eight ankle pairs was able to reject the null hypothesis that the
response difference was zero with probability (power) 0.80. TheType I error probability associated with this test of this null hy-
pothesis was 0.05. Because two pairs of treatment were investi-
gated, the total sample size was 16 goats.
Statistical analyses were performed with use of SPSS software
(version 18.0; Chicago, Illinois). Variables with normal distribution
are reported as mean and 95% conﬁdence intervals (CIs). Data with
skewed distribution are reported as median and range. The Wil-
coxon signed ranks test was used to calculate p-values of matched
pairs (DBM vs control and DBM þ PRP vs control). The Manne
Whitney U test was used to compare the treatment effect of DBM
(i.e., difference of DBM and internal control) with the treatment
effect of DBM þ PRP (i.e., difference of DBM þ PRP and internal
control). MARs of different administration periods were compared
using the Wilcoxon signed ranks test.
The results were considered statistically signiﬁcant if the p-
value was less than 0.05 for the primary outcome (i.e., BV/TV). To
correct for multiple testing, Holm’s method was used for the sec-
ondary outcome parameters (macroscopy, histology, histo-
morphometry, and ﬂuorescence microscopy)29,30. Because four
secondary outcome measures were used, adjusted p-values with
signiﬁcance levels of 0.01 (i.e., 0.05/4) and higher were appropriate.
Results
General results
The surgical procedures and functional recovery were un-
eventful in 15 goats. After 24 h, no signs of limping or abnormal
motion were observed. In one goat, there was a technical failure of
the instruments, resulting in an OCD drilled completely through the
talus. In consultationwith the Animal Care and Use Committee, this
animal was terminated and replaced by another, which had no
complications. The mean body weight was 73.5 (95% CI, 67.1e
79.8) kg before surgery and 69.3 (95% CI, 63.7e75.0) kg at 24 weeks
follow-up.
Macroscopy
All OCDs were macroscopically covered with ﬁbrocartilaginous
tissue. The mean ICRS cartilage repair assessment was 8.0 (95% CI,
7.3e8.7) for DBM treatment, 8.4 (95% CI, 7.4e9.5) for DBM control,
6.9 (95% CI, 5.3e8.6) for DBMþ PRP treatment, and 7.4 (95% CI, 6.0e
8.9) for DBM þ PRP control (differences not statistically signiﬁcant)
(Fig. 2). The surrounding talar cartilage and opposite joint surfaces
appeared unaffected.
Fig. 2. Examples of the best (A; ICRS cartilage repair assessment, 10) and worst (B; ICRS cartilage repair assessment, 3.5) macroscopic appearance of the OCDs (arrows) after 24
weeks of healing. Both are control specimens.
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There were no signiﬁcant differences between groups on the
primary outcome measure BV/TV or any of the other mCT param-
eters in either volume of interest (Fig. 3 and Table I). In the
DBM þ PRP treatment group, there were no statistically signiﬁcant
differences between goats with high concentrations of PRP and
those with low concentrations. For example, BV/TV in the complete
OCDs of the four goats with the highest PRP concentrations was
0.49 (95% CI, 0.39e0.58), compared to 0.55 (95% CI, 0.30e0.80) in
the four goats with the lowest PRP concentrations (P ¼ 1.00).
Histology
Four types of healing patterns were recognized (Fig. 4). Type 1
was almost completely healed (>75% repair). In type 2, the sub-
chondral bone was (almost) restored but a cystic lesion underneath
the restored bone remained. Type 3 was characterized by regen-
eration from the margins and bottoms of the defects but a super-
ﬁcial defect remained (25e75% repair). In type 4, no or onlyFig. 3. Bar chart showing the mean and 95% CI of the BV/TV, according to mCT analysis, of (A)
signiﬁcant (P > 0.05).minimal healing was observed (<25% repair); the original defects
were ﬁlled with fatty and connective tissue, and the surface was
covered with a thin layer of cells. There was high variation in
healing patterns between animals (Fig. 5), while the left and right
tali within a single animal showed more consistency. There were
remnants of DBM in two cases: one DBM treatment and one
DBMþ PRP treatment. Additionally, macrophageswere observed in
ﬁve defects: one DBM treatment, one DBM control, and three
DBM þ PRP control. Osteoclasts were not found.
Histomorphometry
There were no statistically signiﬁcant differences in histo-
morphometry between the groups for any of the parameters
analyzed in any of the areas of interest (Table II).
Fluorescence microscopy
There were no statistically signiﬁcant differences between the
groups (Table III). Some data were missing due to either no bone orthe complete defect and (B) the central 3  5 mm. The differences were not statistically
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C.J.A. van Bergen et al. / Osteoarthritis and Cartilage 21 (2013) 1746e17541750no detectable label in the measurement ﬁeld, especially in the
fourth administration period (week 18e23). The MAR of the second
administration period (week 6e12) of each group was signiﬁcantly
higher than that of the ﬁrst administration period (week 1e6). The
MAR did not change signiﬁcantly in subsequent periods.
Discussion
This study aimed to evaluate the effectiveness of DBM and PRP
in the treatment of ankle OCDs in goats. A previously established
goat model was utilized, enabling evaluation of treatment of a
standard OCD of the talus in a large animal with qualitative and
quantitative analyses20. The control OCDs in this study can be
regarded as bone marrow stimulation of the defect without addi-
tional ﬁlling.
In contrast to our hypotheses, DBM did not result in improved
repair compared to the control defects, nor did PRP enhance the
regenerative capacity of DBM. Therewere no statistically signiﬁcant
differences between the groups on the primary outcome BV/TV, as
measured by mCT, or the secondary outcomes, as measured by
macroscopy, histology, histomorphometry, and ﬂuorescence mi-
croscopy. However, some generalization uncertainty remains
because of the dispersion of the outcome data, as demonstrated by
the width of the 95% CIs (see Fig. 3 and Tables I and III). There were
no observations of abnormalmotion or limping after 24 h. Although
a signiﬁcantly higher MAR was shown after the ﬁrst 6 weeks, this
ﬁnding was similar in each treatment group (see Table III).
Gao et al. investigated the effect of allogeneic rabbit deminer-
alized cortical and trabecular bone matrix for the treatment of 3-
mm OCDs in 10 young rabbit medial femoral condyles8. At 6 and
12 weeks postoperatively, the defects were repaired up to 95% of
their depth but there was a clear difference between cortical and
trabecular DBM. In most of the specimens treated with cortical
DBM, the repair tissue was composed of subchondral bone and a
top layer of cartilage that was smooth and integrated with the
adjacent cartilage. In contrast, trabecular DBM resulted in a ﬁbril-
lated surface without integration with the adjacent cartilage. Gur-
evitch et al. studied 1.5-mm OCDs in the intercondylar region of rat
knees after implantation of cortical DBM particles31. In contrast to
Gao et al., the former authors observed no proper healing of the
defects after a follow-up of up to 24 weeks. Likewise, Dahlberg and
Kreicbergs investigated allogeneic DBM in intercondylar groove
OCDs of rabbit distal femora, and found absence of bone differen-
tiation toward the joint surface32. They concluded that the synovial
environment seemed to prevent bone formation otherwise induced
by DBM. The present study investigated cortical DBM for talar OCDs
and found no beneﬁcial effect. The differences in outcome between
our study and the former studies might be due to the fact that we
studied larger and older animals with larger OCDs. Additionally, an
important difference between the studies is the joint investigated;
the knee and ankle joints differ in congruency, cartilage thickness,
and loading characteristics33e35. These joints might thus not be
reliably compared in osteochondral defect healing models.
In general, the effectiveness of DBM depends on numerous
variables, including the age of the donor36, the tissue bank and the
lot25,37,38, prolonged heat treatment39, the size or shape of the graft
particles40, the nature of the carrier material, the extent of residual
bonemineral content41, and themethod of sterilization42. However,
most of these variables are not applicable to the commercially
available DBM used in the current study. This type of DBM has
shown consistent composition and proven effectiveness in previous
studies using a heterotopic bone formation model and an in vitro
model12,25,43. Possibly, the natural circumstances of the joint (i.e.,
high loading forces and possible intrusion of ﬂuid into the OCD)
might preclude the effectiveness of the DBM in the present study.
Fig. 4. Goldner-stained sections showing four types of healing. Type 1 (A) was almost completely healed. In type 2 (B), the subchondral bone was (almost) restored but a cystic
lesion underneath the restored bone remained. Type 3 (C) was characterized by regeneration from the margins and bottoms of the defects but a superﬁcial defect remained. In type
4 (D), no or only minimal healing was observed. The original defects are indicated with black lines. Subtle differences in size of the defects may be due to slice preparation.
C.J.A. van Bergen et al. / Osteoarthritis and Cartilage 21 (2013) 1746e1754 1751Remnants of the DBMwere found in two specimens, suggesting not
all the material had remodeled. Furthermore, DBM was used as a
xenograft; that is, human DBMwas implanted in caprine OCDs. This
might theoretically inﬂuence the effectiveness of DBM. However,
the use of human DBM in animals did not seem to affect positive
results in other studies19,25. Hence, this aspect is probably not a
good explanation for the lack of effectiveness. The immune
response of the animals was not clearly related to the implantation
of DBM; macrophages were observed in one DBM specimen and in
four control specimens.
The addition of PRP to DBM has led to equivocal results in the
literature. Butcher et al. found a signiﬁcant increase in DNA contentFig. 5. Distribution of histologic healing types.andmineralization level by adding PRP toDBM in vitro44. Likewise, a
viable osteochondral construct has been created with DBM and PRP
ex vivo45. In contrast, Ranly et al. found a neutral or even inhibitory
effect of PRP to the ectopic formation of bone induced by DBM in a
nude mouse model19. This negative effect of PRP to DBM may have
been caused by the activation with thrombin25. Han et al. demon-
strated that PRP can increase the osteoinductivity of DBM, but only
when it has not been activated by thrombin25. Even though in the
present study the PRP was not activated with thrombin either, a
beneﬁcial effect of PRP could not be demonstrated.
Strengths of this study include the use of an established model
with a large animal; a power analysis to identify the minimal
number of animals; an internal control in each goat; and
numerous qualitative and quantitative analyses after relatively
long follow-up.
The study also has limitations. There was a single follow-up
assessment of 24 weeks. This way, the number of goats required
for the study could be limited to 16. Instead of using additional
animals for shorter follow-up assessments, ﬂuorochrome labels
were injected at variousmoments during the follow-up period. This
allowed analysis of the speed of repair during the recovery period
and made the inclusion of additional animals unnecessary. Another
limitation was the variable concentration of platelets in the PRP.
The mean concentration was approximately four times that of
unprepared caprine whole blood, but the dispersion was high. This
variation was also observed in previous studies15,23, and might be
due to either the preparation or the analysis of PRP. Although both
systems e GPS II for preparation and XE-5000 for analysis e have
been developed for human blood, others have successfully used
them in animals; e.g., a GPS II system for bovine blood (increasing
the platelet concentration fourfold)24, and an XE-2100 analyzer for
rat PRP46. We therefore believe the systems can be used in other
species. We also believe the observed variation in platelet
Table II
Outcome of histomorphometry
Treatment group Bone% Osteoid% N.Oc (104/mm2) N.Ob (104/mm2)
Center Sides and
bottom
Surface Center Sides and
bottom
Surface Center Sides and
bottom
Surface Center Sides and
bottom
Surface
DBM Treatment 7.7 (0.0e64.3) 55.1 (25.7e75.1) 0.0 (0.0e65.5) 0.1 (0.0e2.6) 1.1 (0.4e1.6) 0.0 (0.0e8.1) 3.1 (0.0e8.0) 6.4 (4.0e7.9) 0.0 (0.0e12.8) 0.0 (0.0e9.0) 2.7 (1.3e8.5) 0.0 (0.0e9.4)
Control 33.8 (0.0e74.9) 58.8 (22.6e68.9) 5.5 (0.0e71.5) 0.1 (0.0e1.6) 1.3 (0.0e2.9) 0.0 (0.0e7.6) 4.3 (0.0e8.3) 6.8 (3.8e10.1) 2.3 (0.0e24.8) 0.2 (0.0e4.0) 2.9 (0.0e16.0) 0.9 (0.0e3.6)
DBM þ PRP Treatment 0.0 (0.0e64.7) 44.8 (29.5e83.6) 9.0 (0.0e52.1) 0.0 (0.0e1.4) 0.8 (0.1e3.3) 0.1 (0.0e10.7) 0.0 (0.0e8.5) 6.1 (1.7e8.9) 2.9 (0.0e14.1) 0.0 (0.0e7.0) 3.7 (0.0e9.1) 2.4 (0.0e14.9)
Control 2.6 (0.0e56.5) 58.0 (26.4e87.2) 0.0 (0.0e31.2) 0.1 (0.0e3.9) 0.9 (0.2e2.7) 0.0 (0.0e13.5) 1.3 (0.0e6.8) 6.2 (5.3e9.2) 0.0 (0.0e8.4) 1.1 (0.0e5.6) 4.2 (0.0e17.1) 0.0 (0.0e12.1)
The values are presented as the median, with the range in parentheses.
There were no statistically signiﬁcant differences between the groups.
N.Ob ¼ number of osteoblasts and N.Oc ¼ number of osteocytes.
Table III
Outcome of ﬂuorescence microscopy
Treatment group MAR week 1e6 (mm/d) MAR week 6e12 MAR week 12e18 MAR week 18e23
Center Sides and
bottom
Surface Center Sides and
bottom
Surface Center Sides and
bottom
Surface Center Sides and
bottom
Surface
DBM Treatment 0.29 (0.19e0.39) 0.35 (0.26e0.45) 0.31 (0.20e0.42) 1.02 (0.39e1.66) 1.02 (0.82e1.22) 0.63 (0.52e0.74) 1.07 (0.52e1.62) 1.16 (0.91e1.41) 2.20 1.50
(0.81e2.19)
1.09
(0.99e1.19)
NA
Control 0.47 (0.22e0.71) 0.51 (0.36e0.66) 0.53 (0.36e0.68) 1.13 (0.99e1.26) 1.09 (0.90e1.27) 1.13 (0.63e1.63) 1.72 (0.75e2.70) 1.31 (1.02e1.59) NA NA 1.24
(0.93e1.55)
NA
DBM þ
PRP
Treatment 0.45 (0.14e0.75) 0.52 (0.40e0.63) 0.36 (0.28e0.43) 1.18 (0.83e1.54) 1.53 (1.15e1.92) 1.01 (0.97e1.04) 1.09 (1.01e1.17) 1.04
(0.61e1.48)
1.43
(0.65e2.21)
1.40
(0.83e1.97)
1.11 NA
Control 0.41 (0.25e0.56) 0.43 (0.32e0.54) 0.31 (0.19e0.42) 1.11 (0.95e1.27) 1.38 (0.82e1.93) 0.95 (0.47e1.43) 0.98 (0.71e1.25) 1.42 (0.84e1.99) NA 1.46 1.56
(0.63e2.50)
NA
The values are presented as the mean, with the 95% CI in parentheses.
The MAR of the second administration period (week 6e12) of each group was signiﬁcantly higher than that of the ﬁrst administration period (week 1e6). The MAR did not change signiﬁcantly in subsequent periods.
NA ¼ not applicable.
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statistically signiﬁcant difference (P ¼ 1.0) in outcome between
specimens with high concentrations and those with low concen-
trations of PRP. Besides, the ideal concentration of PRP remains
unknown14,47. Further studies are indicated to determine the
optimal concentration of PRP as well as the ideal preparation of
DBM before they can be uniformly investigated in (pre)clinical
studies.Conclusion
DBMwith or without PRP was not beneﬁcial in the treatment of
OCDs of the talus in goats.Author contributions
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